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DOI 10.1186/s12885-015-1460-1RESEARCH ARTICLE Open AccessIdentification of markers that functionally define a
quiescent multiple myeloma cell sub-population
surviving bortezomib treatment
Alfred Adomako1†, Veronica Calvo1†, Noa Biran1,3, Keren Osman1,3, Ajai Chari1,3, James C Paton5,
Adrienne W Paton5, Kateri Moore4, Denis M Schewe1 and Julio A Aguirre-Ghiso1,2,3,4*Abstract
Background: The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz)
treatment remain unclear. We hypothesized that studying the biology of bortezomib-surviving cells may reveal
markers to identify these cells and survival signals to target and kill residual MM cells.
Methods: We used H2B-GFP label retention, biochemical tools and in vitro and in vivo experiments to characterize
growth arrest and the unfolded protein responses in quiescent Bz-surviving cells. We also tested the effect of a
demethylating agent, 5-Azacytidine, on Bz-induced quiescence and whether inhibiting the chaperone GRP78/BiP
(henceforth GRP78) with a specific toxin induced apoptosis in Bz-surviving cells. Finally, we used MM patient
samples to test whether GRP78 levels might associate with disease progression. Statistical analysis employed t-test
and Mann-Whitney tests at a 95% confidence.
Results: We report that Bz-surviving MM cells in vitro and in vivo enter quiescence characterized by p21CIP1
upregulation. Bz-surviving MM cells also downregulated CDK6, Ki67 and P-Rb. H2B-GFP label retention showed
that Bz-surviving MM cells are either slow-cycling or deeply quiescent. The Bz-induced quiescence was stabilized
by low dose (500nM) of 5-azacytidine (Aza) pre-treatment, which also potentiated the initial Bz-induced apoptosis.
We also found that expression of GRP78, an unfolded protein response (UPR) survival factor, persisted in MM quiescent
cells. Importantly, GRP78 downregulation using a specific SubAB bacterial toxin killed Bz-surviving MM cells. Finally,
quantification of Grp78high/CD138+ MM cells from patients suggested that high levels correlated with progressive
disease.
Conclusions: We conclude that Bz-surviving MM cells display a GRP78HIGH/p21HIGH/CDK6LOW/P-RbLOW profile, and these
markers may identify quiescent MM cells capable of fueling recurrences. We further conclude that Aza + Bz treatment of
MM may represent a novel strategy to delay recurrences by enhancing Bz-induced apoptosis and quiescence stability.Background
The overall survival of patients with multiple myeloma
continues to improve, in large part due to proteasome in-
hibitors (PIs) and immunomodulatory agents [1, 2]. How-
ever, the majority of patients treated with these drugs
inevitably relapse after variable remission periods [3].* Correspondence: julio.aguirre-ghiso@mssm.edu
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unless otherwise stated.Much effort has been spent in understanding how PIs in-
duce pathways that regulate cell death during the acute
treatment of these patients [4]. Similar effort has been
placed in finding ways to maximize PI effectiveness and
duration of response. However, less is known about the
biology of residual MM cells that survive therapy, how to
identify them, and how they persist after treatment [5, 6].
Currently, there are no universal criteria for identifying
and tracking residual cells in MM patients in remission
[7]. Understanding the biology and characteristics of MM
residual disease, thus, represents a key avenue to prevent
relapses.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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cell intrinsic and stromal pathways [8]. Among these
pathways, PIs are powerful activators of the unfolded
protein response (UPR). This pathway has the ability to
induce cell death but it also can induce growth arrest
and survival as a first response to endoplasmic reticulum
(ER) stress. We previously showed that acute exposure
to bortezomib (Bz) treatment activated a canonical
PERK-eIF2α-CHOP pathway that resulted in the major-
ity of MM cells entering cell death [6]. However, MM
cells surviving Bz treatment downregulated eIF2α phos-
phorylation, upregulated the survival chaperone BiP/
GRP78 and entered a prolonged G0-G1 cell cycle arrest.
Dephosphorylation of eIF2α in quiescent surviving MM
cells was key for survival because inhibition of
GADD34/PP1C, an eIF2α phosphatase, killed almost all
surviving MM cells [6]. While these studies identified a
survival mechanism for MM cells that persist after Bz
treatment, they did not explain what cell cycle machin-
ery components regulated the prolonged growth arrest
and survival after Bz treatment. Further, the role of BiP/
GRP78, an HSP70 family member for which inhibitors
are in development [9], in Bz-surviving MM cells was
also unknown.
Here, we show that MM cells that survive prote-
asome inhibitors display a GRP78HIGH/p21HIGH/
CDK6LOW/P-RbLOW profile. We also provide prelimin-
ary evidence that higher levels of GRP78 detected in
MM patient bone marrow biopsies may be present in
patients with more aggressive disease and that GRP78
downregulation potentiated Bz killing. Thus, these
markers may pinpoint quiescent MM cells with the
ability to persist after treatment and sensitivity to
Grp78 inhibition. We also show that apoptosis can be
potentiated and quiescence extended by a sequential 5-
azadeoxycitidine and Bz treatment. This drug combin-
ation schedule might represent a novel strategy to
potentiate Bz efficacy in MM disease treatment.
Methods
Reagents, cell lines, tissue culture and quantitative
reverse transcription-PCR
Antibodies: Anti-BiP/GRP78 [610979, BD]; Anti-CD138
[sc-5632, Santa Cruz]; Anti-Ki67 [9449, Cell Sig.]; Anti-
P-Rb (Ser807/811) [8516, Cell Sig.]; Anti-P-Rb (Ser249/
Thr252) [sc-377528, Santa Cruz]; Anti-p21 [2947, Cell
Sig]; Alexa Fluor® 488 Goat Anti-Mouse, [A-11001; Invi-
trogen]; Alexa Fluor® 568 Goat Anti-Rabbit, [A-11008;
Invitrogen]). Vectastain ABC kit and DAB peroxidase
substrate kit was used for IHC developing [Vector lab].
Bortezomib (S1013, Selleck Chemicals) was used to treat
RPMI8226 (CCL-155, ATCC) and U266 (TIB-196, ATCC)
cells at 4 nmol/L or 8 nmol/L Bz for 24 h. The drug was
removed by washing 3x with PBS and then re-plated infresh medium (RPMI-1640 with 10% FBS). Cells were
cultured according to ATCC recommendations. In 5-
azacytidine (Aza) (A2385, Sigma) experiments, the cells
were pre-treated for 4 days with 500 nmol/L Aza (and
replaced every 48 h) before Bz treatment. Total RNA was
extracted using Trizol. Primers used are in [Additional file 1:
Table S1].
Mouse xenograft studies
Institutional Animal Care and Use Committees (IACUC)
at Mount Sinai School of Medicine (MSSM) approved
all animal studies. Protocol ID: 11-0032PRYR1. ATCC-
derived RPMI8226 and U266 cells were expanded and
pulsed for 24 h with 8 nM Bz or DMSO vehicle control.
Cells were then washed and viability was assessed by
Trypan blue exclusion assay. Equal number of live (1 ×
106) cells was then resuspended in PBS with 50 % Matrigel
(356231, BD), and injected s.c. into 4- to 6-week-old male
NSG mice (Charles River). Tumor volumes were mea-
sured and calculated using the formula (D × d2)/2, where
D is the longest and d is the shortest diameter. All points
represent independent biological samples with error bars
representing standard deviations and statistical signifi-
cance determined using a Mann–Whitney test.
Nuclear and chromatin extraction and western blots
After drug treatments, cells were washed with PBS and
resuspended in 2 mL of Buffer A (10 mM HEPES pH =
7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34M sucrose, 10 %
glycerol) with 1 mM DTT, protease inhibitors, and 0.1 %
Triton X-100 on ice for 7 min. The cells were then spun
at 4,000 rpm and 4°C for 4 min. The pellets, containing
the nuclear fractions, were resuspended in 300 μL of 2×
Laemmli sample buffer per 10 × 106 cells and then
heated to 95°C for 10 min for western blotting. For chro-
matin fractions, the nuclear extracts were treated with
“no salt buffer” (3 mM EDTA and 0.2 mM EGTA) before
addition of 2× Laemmli sample buffer. For whole-cell
lysates, cells were lysed for 30 min with lysis buffer
containing 1 % Triton X-100, 50 mM Hepes, pH 7.5,
150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM ortho-
vanadate, 1 mM NaFl, and protease inhibitors. Western
blots were performed as previously described [10] and
imaged using Image Quant LAS (GE).
Patient samples
Bone marrow aspirates (BMA) from multiple myeloma
patients were collected in heparinized tubes following an
Icahn School of Medicine Institutional Review Board
approved protocol (Number: MSSM HS 10-00105). The
BMAs were then subjected to density gradient centrifu-
gation using Ficoll-Paque Plus (17-1440-02, GE). The
isolated bone marrow mononuclear cells were then incu-
bated with CD138 MicroBeads (130-090-503, Miltenyi)
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CD138-positive cells were fixed and spun onto slides. To
test for enrichment, mononuclear cells before and after
separation were stained for CD138. RPMI8226 cells were
stained as a positive control. The percentage of CD138-
positive cells increased from about 8 % pre-separation to
97 % post-separation in all patients. The patient slides were
stained with BiP/GRP78 primary antibody overnight and
Alexa Fluor® 488 goat anti-mouse secondary antibody the
next day. For controls, slides were stained with the sec-
ondary antibody alone. The slides were imaged using
Leica DM6000 and quantified with ImageJ (NIH).
Immunofluorescence (IF) and Immunohistochemistry (IHC)
For IF analysis of cytospins, cells were separated by dens-
ity gradient centrifugation using Ficoll-Paque Plus after
treatment to remove dead cells. The live cells were then
fixed in 4 % paraformaldehyde in PBS (15 mins) and cyto-
spun onto slides. Slides were then washed, permeablized
using 0.5 % Triton X-100 and blocked for an hour with
3 % normal goat serum and 3 % BSA in PBS. The slides
were then incubated with primary antibodies or diluent
(1 % BSA in PBS) overnight at 4°C. After washing, the
slides were incubated with secondary antibodies. The
slides were then washed and mounted with Prolong gold
anti-fade reagent with DAPI [P36931, Invitrogen]. Slides
were images using a Leica DM5500B microscope and
analyzed using MetaMorph®. For IHC analysis of tumors,
tissues were fixed in 4 % PFA for 24 h, and then trans-
ferred to 70 % ethanol until processing for paraffin em-
bedding and sectioning into 4-um-thick slices. Slides were
deparaffinized and rehydrated through xylene and ethanol
washes, and antigen unmasking was performed by heat-
induced retrieval in citrate buffer. Quenching of endogen-
ous peroxidase activity was done with 3 % H2O2. After
blocking with 3 % normal goat serum in 3 % BSA/PBS for
1h, slides were incubated with primary antibodies over-
night at 4°C. After washing, either fluorophor-conjugated
secondary antibody was used and then mounted or an
avidin/biotin peroxidase system was used and developed
with peroxidase substrate kit [Vector lab]. In the latter case,
VectaMount mounting media was used [Vector lab]. For
quantification purposes, at least 10 randomly selected
20x fields were counted.
Generation of the H2B-GFP tagged line and label
retention assay
The Tet-inducible H2B-GFP construct was a kind gift
from Dr. Kateri Moore [11]. The plasmid was transfected
in 293T cells. Lentiviral particles were harvested from
293Tcells and used to infect RPMI8226 cells. The infected
cells were selected for stable expression using puromycin
(1 ug/mL). Upon induction of H2B-GFP with doxycycline
(1 ug/ml), high expressers were sorted using FACSAriaII(BD). For label retention experiments, the cells were in-
duced with doxycycline for 6 days and released at the time
of Bz treatment. Label retention was analyzed using FACS
LSR Fortessa (BD). For viability assessment, Trypan blue
exclusion assay was performed.
Results
Bortezomib-surviving MM cells display a CDK6LOW/p21HIGH
quiescent profile
We used a stable RPMI 8226 cell line virally transduced
with a lentivirus containing a Tet-inducible H2B-GFP con-
struct (see Methods). This inducible H2B-GFP label reten-
tion system allows marking the nucleosomes of cells by
inducing the H2B-GFP transgene with Tetracycline. After
de-induction (Tetracycline removal), only cells that do not
divide and thus do not or slowly turnover their nucleo-
somes can be tracked as quiescent tumor cells for very
long periods [12]. Tetracycline-treated RPMI-Tet-H2B-
GFP cells (H2B-GFPHIGH) were washed, pulsed for 24 h
with Bz (4 nM and 8 nM) and then followed for 3 days
by FACS [Fig. 1a-b]. Using gates that detected viable
H2B-GFPHIGH label retaining cells, we found that while
DMSO-treated cells lost most of their labeling within 3
days (~8.5 % +/-0.9), ~30 % of the Bz-treated cells contin-
ued to retain high H2B-GFP labeling (~3.6 fold more in
the MFI >103) [Fig. 1a-b]. By 6 days, while label retention
continued to decrease in control cells, Bz-surviving cells
still displayed a 14- to 20-fold increase in H2B-GFPHIGH
cells [Fig. 1c]. U266 cells pulsed with an equivalent dose
of the PI MG132 also remained quiescent up to 8-10
days before entering log-phase of proliferation [Additional
file 2: Figure S1A]. In our previous study [6] and ex-
periments here, we also used the proteasome inhibitor
MG132 to show that the effects are due to proteasome
inhibition and not some unspecific Bz effect. Using these
two inhibitors, we reported previously that cells surviving
Bz treatment are not irreversibly damaged and continu-
ously entering apoptosis after drug washout, but rather
entering a growth arrest that was measured using cell
cycle profiling, P-Rb phosphorylation and label retention
assays [6]. In addition, that the surviving quiescent frac-
tion is viable is further supported by the detection of label
retention of H2B-GFP [Fig. 1a].
Analysis of the viable quiescent Bz-surviving MM cells
using immunofluorescence and western blot (nuclear frac-
tion) showed that these cells were enriched for the cyclin-
dependent kinase inhibitor p21CIP1 mRNA and nuclear
protein [Fig. 1d-f]. The CDK inhibitors p15 and p16
mRNAs were also induced but p21CIP1 mRNA showed
the strongest induction [Additional file 3: Figure S2E],
which could be followed by Western blot and IF. This
was observed at the end of the acute phase (Day 0) and at
3, 6 and 7 days after washout of the 24 h pulse of Bz
[Fig. 1d-f]. Furthermore, H2B-GFPHIGH cells expressed
Fig. 1 a Representative histogram of FACS analysis of H2B-GFP label retention in RPMI8226-Tet-H2B-GFP cells 0 and 3 days after a 24-h pulse with Bz
(4 nM and 8 nM). Percentages = Percent of H2B-GFPHIGH ± standard deviation. b Quantification plot of H2B-GFPHIGH label retention. ****, P<0.0001 comparing
surviving day 3 DMSO to 4 nM Bz or 8 nM Bz, (unpaired t test). c Representative histogram of FACS analysis of H2B-GFP label retention 6 days after 24-h pulse
with Bz. Percentage of cells was calculated using BD FACSDiva software (BD). d Western blots for p21CIP1 protein in nuclear extracts of cells surviving
proteasome inhibition 0, 3 and 6 days after drug washout. Total Histone H3 was used as a loading control. e & f Detection and quantification of
p21CIP1 in H2B-GFPHIGH label-retaining cells at 3 and 7 days after drug washout by IF. Quantification was done using ImageJ. * p = 0.0361 comparing day 3
H2B-GFP-positive cells in DMSO vs. 4 nM Bz (unpaired t test). * p = 0.0475 comparing day 7 H2B-GFP-positive cells in DMSO vs. 4 nM Bz (unpaired t test).
gWestern blots for CDK6 protein in cells surviving proteasome inhibition 3 days after drug washout. GAPDH was used as a loading control. Scale bar =20 μm
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DMSO controls [Fig. 1e-f]. Arguing for a G0-G1 arrest,
p21CIP1 induction correlated with the downregulation of
CDK6 protein as measured by Western blot [Fig. 1g] and
with decreased levels of cyclin-D3 and CDK4 protein
levels in proteasome inhibitor-pulsed cells [Additional file 2:
Figure S1B]. This is in agreement with our data from
[Fig. 1a-c] showing the existence of a deeply quiescent
population in vitro.
To determine whether Bz-surviving cells would also
remain quiescent in vivo, RPMI8226 cells were pulsed
for 24 h with Bz (8 nM or DMSO as control, n = 5 per
group), washed and equal number of viable cells were
injected into NSG mice. By Day 29-30, palpable tumors
were detected in the DMSO group. The Bz pulse induced
a delay of 2-5 days in tumor take and a significant differ-
ence in final tumor volume between DMSO and Bz mice
[Fig. 2a]. A longer delay in tumor take was observed in
mice injected with U266 cells, which also entered a longer
quiescence in vitro [Additional file 2: Figure S1A]. By 80Fig. 2 a Tumor latency and volume plot. Mice were injected with RPMI822
Bz (n = 5). Palpable tumors were observed in DMSO treated at day 28 (none i
Bz mice at day 34 suggesting a 5-day latency period until tumor growth. *p =
b Tumor weight plot of U266 cells treated as in [A], excised on day 86 after in
at day of sacrifice. Tumors were in some cases excised with surrounding subc
determined as best as possible by visual inspection. c IHC detection of p21CIP
with DMSO or 8 nM Bz (n = 3). Quantification of percentage positive nuclear p
(unpaired t test). Scale bar =25 μm. Insets show details of p21 negativdays, there were palpable tumors in 5/10 of the mice
injected with DMSO treated MM cells and no obvious
palpable tumors in the 10 mice that received 8 nM Bz-
treated cells. However, upon necropsy, we found that the
mice injected with Bz-treated cells contained small dor-
mant tumor nodules [Fig. 2b]. The dormant phenotype
was tested to determine whether the in vivo growth
suppression was due to increased cell death, quiescence or
both. Sections of these tumors were stained for the apop-
tosis marker cleaved caspase-3 and the quiescence marker
p21CIP1. This analysis revealed that the quiescence induc-
tion in Bz-surviving cells was also recapitulated in vivo.
Bz-pulsed-RPMI8226- and -U266-derived tumors showed
elevated levels of p21 nuclear expression compared to con-
trol tumors [Fig. 2c] at day of sacrifice, while no significant
differences were detected in the levels of apoptosis as indi-
cated by cleaved caspase-3 immunostaining [Additional
file 2: Figure S1C]. Together these data argue that, while
a fraction of Bz-surviving cells may be sensitized to apop-
tosis even after drug-washout and this contributes to the6 cells that had been pulsed for 24 h with either DMSO (n = 5) or 8 nM
n 8 nM Bz) and measurable at day 29. Tumors were measurable in 8 nM
0.0245 comparing DMSO to 8 nM Bz mice at day 34 (unpaired t test).
jection. *p = 0.0322 (unpaired t test). Representative images of tumors
utaneous tissue. Dotted lines indicate the margins of the tumors
1 levels in tumors derived from RPMI8226 and U266 cells pulsed for 24 h
21CIP1 in tumor sections. *p = 0.05 comparing DMSO vs. 8 nM Bz
e (DMSO) and positive (8 nM Bz) cells
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comes deeply quiescent (or slow cycling) for variable
periods of time after drug exposure. We further con-
clude that the PI-induced slow-cycling or quiescence
is associated with a label-retaining CDK6LOW/p21HIGH
profile that was also previously reported by us (6).
A Low-dose 5-aza-cytidine treatment potentiates
Bz-induced cell death and deep quiescence
In MM and other cancers the promoters of many tumor
suppressors including p21CIP1, p15INK4B, p16INK4A and
apoptosis inducers are hypermethylated during trans-
formation from monoclonal gammopathy of unknown
significance (MGUS) to symptomatic MM [13]. Therefore,
demethylating agents such as those used in the treatment
of myelodysplastic syndromes (MDS) [14] may help restore
the expression and response of these genes to stress sig-
nals. We next tested whether pre-treatment of MM cells
with the DNA demethylating agent 5-aza-cytidine (Aza,
500 nM) might render MM cells more permissive for indu-
cing a more long-lasting growth suppression after Bz treat-
ment. MM cells were treated with Aza for 4 days followed
by the 24 h Bz pulse and cell viability and phosphorylation
of Rb (P-Rb) or expression of p21CIP1, Ki67, p15INK4B and
p16INK4A were monitored. As reported, the Aza + Bz treat-
ment enhanced the cell death induced by Bz [Additional
file 3: Figure S2A] [15]. However, the viable surviving frac-
tion after the Aza > Bz treatment displayed a significantly
longer growth arrest (12 days), at least doubling the time
observed with AZA alone or Bz alone treatments (4-6
days) [Fig. 3a]. We found that compared to DMSO con-
trols, DMSO > Bz induced a 64 % decrease in P-Rb mean
fluorescence intensity per cell by the end of the acute
phase (Day 0) [Fig. 3b-c]. The Aza >DMSO and Aza > Bz-
treated cells showed a 77 % and 85 % decrease in P-Rb
levels, respectively. This reduction in P-Rb was more pro-
nounced at 3 days for the Aza + Bz treatment [Additional
file 3: Figure S2B]. Importantly, 6 days after the Aza > Bz
treatment while Bz-only treated cells started to restore
P-Rb levels, Aza > DMSO and Aza > Bz-treated cells
continued to show 94 % and 93 % decrease, respectively
[Fig. 3b-c]. This response was parelleled by sustained de-
crease in Ki67 levels [Additional file 3: Figure S2C-D]
and suggested that Aza alone was sufficient to induce a
growth arrest irrespectively of Bz treatment. However, at
day 6, only the Aza > Bz treatment showed sustained
high p21CIP1 [Fig. 3d-e] along with low levels of the
proliferation markers (Ki67 and P-Rb) [Additional file 3:
Figure S2C-D]. AZA > Bz showed slightly higher Ki67+
percent of cells than AZA >DMSO, which may indicate
cells arrested in G1 (which still stains Ki67) while the
AZA treatment might have the majority of cells in a
G0. It is also possible that these differences might not be
functionally relevant since p21CIP1 positive cells weremore frequent and this may dominate the behavior of
the population. Thus, the Aza > Bz treatment may be
more effective in maintaining a strong p21-associated
G0-G1 arrest. RPMI8226 and U266 cells showed a mar-
ginal benefit of Aza over the induction in p15INK4B,
p16INK4A and p21cip1mRNAs compared to Bz treatment
alone [Additional file 3: Figure S2E]. This argues that the
effects of Aza on p21 protein and cell cycle progression
appear to be related to other changes in gene regulation
and not simply CDKi mRNA upregulation.
Upregulation of GRP78 in Bz-surviving MM cells is
associated with disease progression in patients and
therapy-mediated cell death
We next explored whether GRP78, a UPR-induced gene
upregulated in surviving residual MM cells during quies-
cence [6], was playing a role in their prolonged survival.
We found that Bz-treated cells sustain the expression of
GRP78 [Fig. 4a-b] and this induction was also confirmed
in U266 cells even at 6 days post drug washout [Fig. 4c].
Importantly, the quiescent H2B-GFP label-retaining cells
surviving 3 and 6 days after the Bz pulse showed a signifi-
cant enrichment in GRP78 protein compared to control
cells, as detected by IF [Fig. 4d]. This argues for a specific
upregulation of GRP78 in quiescent cells upon proteasome
inhibition. MG132-surviving RPMI 8226 cells also expressed
more GRP78 suggesting that it is not a Bz-specific effect
[Additional file 2: Figure S1B]. Q-PCR analysis of RPMI
8226 MM cells suggested that GRP78 mRNA was only
induced in the acute phase (Day 0) and returned to
basal levels in the Bz-surviving cells [Additional file 4:
Figure S3A] arguing for a post-transcriptional regulation
of the protein in Bz-surviving cells, possibly through the
5′ internal ribosome entry site on GRP78 mRNA [16].
GRP78 is a well-characterized survival factor across dif-
ferent cancers and in both proliferative and quiescent states
[6, 17, 18]. To provide a preliminary assessment of the
possibility that GRP78 may be used as a survival marker
in MM cells from patients, we measured the levels of
GRP78 in CD138+ sorted cells isolated from BM aspirates
from 12 patients. Control experiments confirmed an al-
most complete enrichment of CD138HIGH cells after mag-
netic bead separation [Additional file 4: Figure S3B-D].
These isolated cells were prepared in cytospins, stained
for GRP78 [Fig. 4e] and the GRP78 MFI was quantified.
Intensities were normalized to the fluorescence intensities
of controls. Bearing in mind that our study is a small sam-
ple size, we found that using the MFI data values, patient
samples separated into 3 groups, low (<1 GRP78 MFI
arbitrary units), medium (1-24 GRP78 MFI) and high (>24
GRP78 MFI) based on calculated median levels of GRP78
MFI levels/cell. All three GRP78LOW patients (25 %) were
characterized as stable disease at time of sample col-
lection. The nine patients with medium and high GRP78
Fig. 3 a Quantification of viable cells in Aza-reprogrammed (500 nM) Bz-surviving RPMI8226 cells compared to Bz only treatment, using Trypan
blue exclusion assay. b & c IF detection and quantification of P-Rb (Ser249/Thr252) in RPMI8226 cells reprogrammed for 4 days ± 500 nM Aza,
pulsed for 24 h with 4 nM Bz and stained 0, 3 (Additional file 3: Figure S2B) and 6 days after drug washout. d & e Detection and quantification of
p21CIP1 in Aza-reprogrammed Bz-surviving RPMI8226 cells via IF. Scale bar =20 μm
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subcategories 2 patients had stable disease (22 %) and one
(11 %) was in remission [Table 1]. Grouping by response
criteria showed that 60 % of patients with stable disease
had GRP78LOW MM cells and 100 % with progressive dis-
ease had CD138+ cells with medium or high GRP78 levels
[Fig. 4f]. Taking into account the limitations of sample
size and heterogeneity in treatment, these data couldbe interpreted as GRP78HIGH levels contributing to a MM
survival advantage. GRP78MEDIUM and GRP78HIGH levels
in CD138+ cells in two patients with stable disease or in
remission might represent MM cells that are slow or
non-proliferative but with a high survival advantage.
We next depleted the GRP78 protein to assess whether
cells hypomorphic for this chaperone were unable to sur-
vive Bz-induced cell death. To this end, we used subtilase
Fig. 4 (See legend on next page.)
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Fig. 4 a Western blots for GRP78 protein in RPMI8226 cells. Due to abundance of GRP78 in RPMI8226 cells, 2 μg of protein per well (instead of
20 μg in other blots) was used in all blots. b IF Detection of GRP78 in Bz-surviving RPMI8226 cells. Fluorescence intensity quantification is shown
as fold increase over the negative control. c Western blots for GRP78 protein in U266 cells 6 days after Bz washout. d Detection and quantification
(right graph) of GRP78 in H2B-GFPHIGH label-retaining cells at 3 and 6 days after drug washout by IF. **** p < 0.0001 (unpaired t test). Scale bar =25
μm. e Detection of GRP78 in cytospins from bone marrow aspirates of MM patients. Representatives of each group (low, medium, and high GRP78
levels) are shown here. Scale bar =20 μm. f Graphical representation of patient groups via GRP78 MFI per cell. Symbols represent stage of each patient.
Patient MM# numbers are shown adjacent to each symbol. P < 0.0001 between groups (one-way ANOVA). g Western blots showing depletion of
GRP78 protein in RPMI8226 cells after treatment with SubAB toxin. Non-functional mutant SubAA272B was used as a control. GAPDH and β-Actin were
used as loading controls. h Cell viability plot of Bz-pulsed RPMI8226 cells, +/- GRP78 depletion via treatment (at two different concentrations) with
SubAB toxin. Non-functional mutant SubAA272B was used as a control. Trypan blue exclusion was used as viability assay
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shown to specifically cleave GRP78 (18, 19) [Fig. 4g]. As a
control, we used a non-functional mutant toxin termed
SubAA272B. Inhibition of GRP78 using the IC50 for SubAB
significantly decreased the viability of the MM cells after
Bz treatment compared to the non-functional mutant
SubA272B [Fig. 4h]. This suggests that GRP78 is a major
survival factor in residual Bz-surviving cells and a poten-
tial target to eradicate these residual cells.
Discussion
Multiple myeloma cells synthesize and secrete large
amounts of immunoglobulins [19] and thus possess a
very tightly regulated ER quality control system. The
proteasome inhibitor bortezomib was the first in its class
to be FDA-approved for treatment of MM patients [20,
21] and second generation agents are now also available
[22]. While proteasome inhibition is a standard of care
for MM, patients invariably relapse. This suggests that a





Ouant Immunoglobulins and Serum immunofixation at co
MM16 64 lgG 2371, monoclonal protein in gamma region
MM17 59 IgG 282, IgA 5083, IgM 16, Two IgA lambda monoclonal b
representing 85 %
MM18 68 IgG 2333, IgA 12, 1gM 20, monoclonal protein seen in ga
MM19 46 IgG 4656, IgA 27, 1 gM 53, monoclonal protein in gamma
MM20 unav IgG 4099, monoclonal band in gamma region
MM21 56 IgG 314, 1 gM <5, IgA <5, faint free kappa band
MM22 52 IgG 453, 1 gM 7, IgA 132, faint IgG lambda band
MM23 70 lgG 840, IgA 9, 1 gM 9, lgG kappa monoclonal spike seen
of monoclonal protein
MM24 57 lgG 255, 1 gM 12, IgA 19, faint free Lambda band seen
MM25 39 lgG 188, IgA 10, 1gM 12, Free monoclonal lambda light c
greatly diminished
MM26 66 lgG 6589, Iga 8, 1 gM <5, lgG kappa monoclonal represen
MM27 54 lgG 5543, IgA 11, 1 gM 19, lgG kappa monoclonal proteinthrough poorly understood mechanisms. We hypothesized
that by exploring the biology of the residual surviving
MM cells we may identify markers for residual cells and
survival mechanisms to target and prevent MM relapse.
We had previously found that Bz-surviving MM cells
entered quiescence and silenced specific components of
the UPR signaling that commonly induce cell death [6, 17,
23, 24]. However, what genes may mark quiescent cells
with enhanced survival properties and what components
of the UPR might promote survival was unknown. Here
we show that after a Bz pulse, the residual cells are for the
most part slow-cycling as expected by the growth arrest
propelled by high eIF2α phosphorylation [25]. However,
we also found a deeply quiescent and viable fraction of
cells that were marked by p21HIGH levels and prolonged
H2B-GFP label retention. In addition to p21 upregulation,
which appeared to be transcriptional, Bz-surviving MM
cells showed loss of CDK6 and consequently loss of P-Rb
protein [6], which could explain the G0-G1 cell cycle ar-
rest in MM cells. These data argue that while slow-cyclingted for BiP levels in CD138+ cells




4.3 201 no Stable disease
and seen, 3.7 106 yes Stable disease
mma region 3.3 175 yes Progression of Disease
(increase in M-spike)
region 3.8 142 no Minimal response/
stable disease
3.7 121 unav Stable Disease
4.7 143 yes Progression of Disease
2.7 170 yes partial response/
stable disease
, representing all 4.5 564 yes Remission (very good
partial response)
3.1 154 yes Progression of Disease
hain, normal Igs 4.7 601 yes Progression of Disease
ting all of total 3.9 166 yes Progression of Disease
4.1 210 yes Progression of Disease
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entering a deeper quiescence. Importantly, these cells
were preferentially enriched for GRP78 arguing they may
be prone to enhanced survival. It is possible that with
repeated cycles of PI treatments used in the clinic more of
the deep quiescent MM cells that survive the treatment
accumulate creating a population that escapes Bz treat-
ment and anti-proliferative drugs, eventually fueling re-
lapses. That these cells may become “professional” ER
stress tolerant is suggested by the upregulation of GRP78
that was also found in MM cells from patients with pro-
gressive disease. Our in vivo data using U266 MM cells ar-
gues that p21HIGH MM cells can be found and may persist
without expanding for ~90 days (~1 year in humans) after
a 24 h pulse with Bz. The lack of apoptosis in these dor-
mant lesions and the upregulation of p21 coupled to no net
increase in tumor mass argues against continuous apoptosis
and in favor of long-term quiescence as a mechanism to ex-
plain de prolonged time to take of these MM cells in vivo.
We propose that in the bone marrow of patients a specific
MM cell subpopulation (CDK6LOW/P-RbLOW/p21HIGH)
may be found dormant after Bz treatment.
Many common quiescence regulators such as the tumor
suppressors p15INK4B [26] and p16INK4A are epigenetically
silenced in cancer [27]. Our data shows that mRNA in-
duction of p15INK4B, p16INK4A and p21CIP1 (and protein)
in surviving MM cells is not greatly increased by an Aza
pre-treatment and Bz pulse. However, the initial apoptosis
and later prolonged growth arrest phase in vitro is more
than doubled in cells treated with Aza and Bz and this
correlated with p21CIP1, Ki67 and P-Rb levels in viable
growth-arrested cells. While we have not performed de-
tailed gene promoter methylation analysis to determine
the targets influenced by the Aza treatment, our data sug-
gested that “reprogramming” with Aza might be amenable
to be used as a way to maximizing the apoptosis but also
quiescence induction effects of Bz.
Our work also tested the role of GRP78, a well-
characterized survival component of the UPR [28] that
is upregulated and promotes drug resistance of quiescent
squamous cell carcinoma (HNSCC) cells [17]. Here we
found that Bz-surviving and quiescent (viable H2B-GFP
label- retaining) MM cells maintained high levels of
GRP78 for many days after drug washout, arguing these
quiescent cells may selectively upregulate this ER chaperone.
This suggests that GRP78 is important for cell survival
during PI-mediated UPR activation in the quiescent MM
cell population. Importantly, targeted depletion of GRP78
enhanced Bz-mediated cell death, justifying further studies
to test if this chaperone might be an amenable therapeutic
target in the resistant residual disease. Overexpression of
GRP78 was correlated with clinical progression in other
cancer models [29–31]. We found GRP78 upregulation
might be associated to disease progression in MM patientsamples. Because our patient sample size is small, we cau-
tiously propose that either in residual MM or recurrent
MM cells, GRP78 is likely to mark a subpopulation with
enhanced survival. Our analysis of patient samples was a
pilot study and larger cohorts of patients tested for GRP78
expression in their MM samples may prove useful to
determine whether this chaperone of the ER is indeed a
marker to distinguish persistent Bz-refractory and/or
recurrent disease.
Conclusions
We conclude that Bz-surviving MM cells display a
GRP78HIGH/p21HIGH/CDK6LOW/P-RbLOW profile. These
markers may pinpoint quiescent MM cells capable of
fueling recurrences. We further conclude that upregula-
tion of GRP78 allows specifically quiescent tumor cells to
survive for prolonged periods and this may be an amen-
able target to kill residual MM cells. Although the mecha-
nisms are incompletely understood, we also conclude that
the combination of Aza and Bz treatments may represent
a novel strategy to delay MM recurrences by enhancing
Bz-induced apoptosis and the stability of the quiescence
program.
Additional files
Additional file 1: Table S1. List of primer sequences used in the study.
Additional file 2: Figure S1. [A] Quantification of viable U266 cells
PI-pulsed (MG132 400nM) using trypan blue exclusion test. [B] Western
blots for CDK4, CDK6, Cyclin D1, Cyclin D3, and GRP78 protein in
MG132-surviving RPMI8226 cells. GAPDH was used as a loading control.
[C] IHC detection of cleaved caspase 3 levels in tumors derived from
RPMI8226 and U266 cells pulsed for 24h with DMSO or 8nM Bz
(n = 3). Quantification of percentage of cleaved caspase 3 positive
cells per tumor sections. * p = n.s comparing DMSO vs. 8nM Bz
(unpaired t test). Scale bar =25 μm.
Additional file 3: Figure S2. [A] Viability of RPMI8226 cells at Day 0
and Day 3 after Bz pulse, with or without Aza pre-treatment (500 nM)
as determined by Trypan blue exclusion test. [B] IF detection of P-Rb
(Ser249/Thr252) in RPMI8226 cells reprogrammed for 4 days ± 500 nM
Aza, pulsed for 24 h with 4 nM Bz and stained 3 days after drug washout.
[C] IF detection and [D] quantification of Ki67 in RPMI8226 cells
reprogrammed for 4 days ± 500 nM Aza, pulsed for 24 h with 4 nM Bz and
stained 6 days after drug washout. [E] qRT-PCR for p15, p16 and p21 mRNA
expression in RPMI8226 and U266 cells after Bz pulse, with or without Aza
pre-treatment. The mRNA levels were normalized with tubulin expression.
Additional file 4: Figure S3. [A] qRT-PCR showing fold increase in
GRP78 mRNA expression in Bz-surviving RPMI8226 cells 0, 3 and 6 days after
drug washout. The mRNA levels were normalized to GAPDH and then
compared to DMSO controls. [B] Detection and [C] quantification plot of
CD138 in MM patient bone marrow aspirates before and after magnetic
beads-based purification of CD138-positive cells. Staining for CD138 in
RPMI8226 cells (right panel) was used as a positive control. [D] Representative
images of CD138 purification in MM patient samples. Scale bar =20 μm.
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